Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
The aim of the study is the identification of cancer patients at increased risk for severe toxicity prior to the administration of 5-FU.
Schneider
H B
HB
Department of Surgery, Universitity of Göttingen, Robert-Koch-Str.40, D-37075 Göttingen, Germany. hbschneider@chirurgie-goettingen.de
Becker
H
H
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003872:Dermatitis / Q000150:complications / Q000188:drug therapy; D003967:Diarrhea / Q000139:chemically induced; D054067:Dihydropyrimidine Dehydrogenase Deficiency; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics* / Q000378:metabolism; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000201:enzymology*; D012307:Risk Factors
D000964:Antimetabolites, Antineoplastic; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil